Why Shares of MannKind Are Up Wednesday
Shares of MannKind (NASDAQ: MNKD) were up 15.6% Wednesday morning after the company released first-quarter earnings after the market closed on Tuesday.
The company specializes in treating endocrine and orphan lung diseases, using its signature dry-powder formulations and inhalation devices. Its shares are down a little more than 16% so far this year.
The healthcare company's first-quarter earnings had plenty of good news for investors. MannKind reported revenue of $41 million, up 239% year over year, including $23 million in revenue from Tyvaso DPI, a pulmonary arterial hypertension (PAH) therapy the company collaborated on with United Therapeutics. The $23 million consisted of $12 million in royalties and $11 million in collaboration and services revenue.
Source Fool.com
MannKind Corp. Aktie
Positive Tendenz für MannKind Corp. mit mehreren Buy- und keiner Sell-Einschätzung.
Ein Kursziel von 6 € für MannKind Corp. zeigt ein leicht positives Potenzial im Vergleich zum aktuellen Kurs von 5.5 €.
